Theodorakopoulou Marieta P, Dipla Konstantina, Zafeiridis Andreas, Sarafidis Pantelis
Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Laboratory of Exercise Physiology and Biochemistry, Department of Physical Education and Sports Science at Serres, Aristotle University of Thessaloniki, Serres, Greece.
Eur J Clin Invest. 2021 Aug;51(8):e13557. doi: 10.1111/eci.13557. Epub 2021 Apr 4.
Cardiovascular disease is the major cause of morbidity and mortality in patients with chronic kidney disease (CKD). Endothelial dysfunction, the hallmark of atherosclerosis, is suggested to be involved pathogenetically in cardiovascular and renal disease progression in these patients.
This is a narrative review presenting the techniques and markers used for assessment of microvascular and endothelial function in patients with CKD and discussing findings of the relevant studies on the associations of endothelial dysfunction with co-morbid conditions and outcomes in this population.
Venous Occlusion Plethysmography was the first method to evaluate microvascular function; subsequently, several relevant techniques have been developed and used in patients with CKD, including brachial Flow-Mediated Dilatation, and more recently, Near-Infrared Spectroscopy and Laser Speckle Contrast Analysis. Furthermore, several circulating biomarkers are commonly used in clinical research. Studies assessing endothelial function using the above techniques and biomarkers suggest that endothelial dysfunction occurs early in CKD and contributes to the target organ damage, cardiovascular events, death and progression towards end-stage kidney disease.
Older and newer functional methods and several biomarkers have assessed endothelial dysfunction in CKD; accumulated evidence supports an association of endothelial dysfunction with outcomes. Future research with new, non-invasive and easily applicable methods could further delineate the role of endothelial dysfunction on cardiovascular and renal disease progression in patients with CKD.
心血管疾病是慢性肾脏病(CKD)患者发病率和死亡率的主要原因。血管内皮功能障碍是动脉粥样硬化的标志,据推测其与这些患者的心血管和肾脏疾病进展有关。
这是一篇叙述性综述,介绍了用于评估 CKD 患者微血管和内皮功能的技术和标志物,并讨论了内皮功能障碍与该人群合并症和结局相关的研究结果。
静脉闭塞体积描记法是评估微血管功能的第一种方法;随后,开发并在 CKD 患者中使用了几种相关技术,包括肱动脉血流介导的扩张,以及最近的近红外光谱和激光散斑对比分析。此外,几种循环生物标志物常用于临床研究。使用上述技术和生物标志物评估内皮功能的研究表明,内皮功能障碍在 CKD 早期发生,并导致靶器官损伤、心血管事件、死亡和进展为终末期肾病。
较旧和较新的功能方法和几种生物标志物已评估 CKD 中的内皮功能障碍;累积证据支持内皮功能障碍与结局之间的关联。未来使用新的、非侵入性和易于应用的方法进行研究,可能进一步阐明内皮功能障碍在 CKD 患者心血管和肾脏疾病进展中的作用。